FDA Advisory Committee Recommended US FDA Approval of Brilinta (Ticagrelor) for Acute Coronary Syndromes
WILMINGTON, DE – July 28, 2010 – AstraZeneca today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca’s investigational drug ticagrelor for the...
Short URL: http://drugrehab.in/?p=70881
Posted by admin
on Jul 29 2010. Filed under drug applications.
You can follow any responses to this entry through the RSS 2.0.
Both comments and pings are currently closed.
